Skip to main content
SpringerLink
Log in

Janssen Pharmaceutica has announced that its risperidone long-acting injection has been shown to decrease hospitalisation rates and medical costs.

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Janssen Pharmaceutica.Fewer Hospitalizations and Lower Medical Costs Seen Among Patients With Schizophrenia Taking Risperidone Long-Acting Injection. Media Release: 6 Oct 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Janssen Pharmaceutica has announced that its risperidone long-acting injection has been shown to decrease hospitalisation rates and medical costs.. Pharmacoecon. Outcomes News 516, 7 (2006). https://doi.org/10.2165/00151234-200605160-00019

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605160-00019

Keywords

Search

Navigation